In fact, MYCN amplification, occurring in around 25% of all primary neuroblastomas and in 30%–40% of all high-risk cases (Pugh et al., 2013; Huang and Weiss, 2013), has since long been known to correlate to poor clinical outcome (Brodeur et al., 1984). The gene discussed is MYCN; the disease is neuroblastoma.